Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats

Nephrology Dialysis Transplantation

Volumn 24, Issue 1, 2009, Pages 73-84

  Kang, Young Sun ^a   Ko, Gang Jee ^a   Lee, Mi Hwa ^a   Song, Hye Kyoung ^a   Han, Sang Youb ^b   Han, Kum Hyun ^b   Kim, Hyoung Kyu ^a   Han, Jee Young ^c   Cha, Dae Ryong ^a  

^a Korea University   (South Korea)

^b Inje University   (South Korea)

^c Inha University   (South Korea)

Author keywords

Albuminuria; Diabetic nephropathy; Enalapril; Eplerenone; Glomerulosclerosis

Indexed keywords

ALBUMIN; ALDOSTERONE; ENALAPRIL; EPLERENONE; GELATINASE A; GLUCOSE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; KIDNEY FUNCTION; KIDNEY MASS; LONG EVANS RAT; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ALBUMINURIA; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BASE SEQUENCE; COLLAGEN TYPE IV; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENALAPRIL; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; GLOMERULAR FILTRATION RATE; MALE; MESANGIAL CELLS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, INBRED OLETF; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 58049209809     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn448     Document Type: Article

References (42)

1. Schmieder RE, Hilgers KF, Schlaich MP et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-1219
2. Brunner HR, Gavras H. Angiotensin blockade for hypertension: a promise fulfilled. Lancet 2000; 359: 990-992
3. Griendling KK, Minieri CA, Ollerenshaw JD et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148
4. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897
5. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999; 41: 402-417
6. Wolf G. Role of reactive oxygen species in angiotensin II-mediated renal growth, differentiation, and apoptosis. Antioxid Redox Signal 2005; 7: 1337-1345
7. Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 2007; 27: 144-152
8. Trachtman H, Weiser AC, Valderrama E et al. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 2004; 172(Suppl 4): S1590-S1594
9. Feria I, Pichardo I, Juarez P et al. Therapeutic benefit of spironolactone in experimental cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52
10. Blasi ER, Rocha R, Rudolph AE et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800
11. Fujisawa G, Okada K, Muto S et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004; 66: 1493-1502
12. Miric G, Dallemagne C, Endre Z. Reversal of cardiac and renal fibrosis by pirfenidine and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001; 133: 687-694
13. Nitta K, Uchida K, Nihei H. Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases. Am J Med 2004; 117: 444-445
14. Campese VM, Park J. Use of antagonists of aldosterone in patients with chronic kidney disease: potential advantages and risks. J Hypertens 2006; 24: 2157-2159
15. Sato A, Hayashi K, Naruse M et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68
16. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49
17. Cha DR, Kim IS, Kang YS et al. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with type 2 diabetes mellitus. Diabet Med 2005; 22: 14-20
18. Ma LJ, Nakamura S, Aldigier JC et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005; 16: 966-976
19. Gilbert RE, Wilkinson BJL, Johnson DW et al. Renal expression of transforming growth factor-β-inducible gene-h3 (ßig-h3) in normal and diabetic rats. Kidney Int 1998; 54: 1052-1062
20. Rocha R, Chander PN, Zuckerman A et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-237
21. Blasi ER, Rocha R, Rudolph AE et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800
22. Feria I, Pichardo I, Juarez P et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52
23. Zhou X, Ono H, Ono Y et al. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004; 24: 242-249
24. Brown NJ, Nakamura S, Ma L. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227
25. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51
26. Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112
27. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836
28. Han KH, Kang YS, Han SY. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006; 70: 111-120
29. Han SY, Kim CH, Kim HS. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372
30. Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006; 29: 211-216
31. Onozato ML, Tojo A, Kobayashi N et al. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007; 22: 1314-1322
32. Kramer AB, van der Meulen EF, Hamming I et al. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 2007; 71: 417-424
33. van den Meiracker AH, Baggen RG, Pauli S. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285-2292
34. Schjoedt KJ, Rossing K, Juhl TR. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542
35. Rachmani R, Slavachevsky I, Amit M. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-475
36. Takebayashi K, Matsumoto S, Aso Y et al. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91: 2214-2217
37. Juknevicius I, Segal Y, Kren S et al. Effect of aldosterone on renal transforming growth factor-β. Am J Physiol Renal Physiol 2004; 286: F1059-F1062
38. Guo C, Martinez-Vaquez D, Mendez GP et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006; 147: 5363-5373
39. Yuan J, Jia R, Bao Y. Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. J Biochem Mol Biol 2007; 40: 180-188
40. Matsumoto S, Takabayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006; 55: 1645-1652
41. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-693
42. Schjoedt KJ, Andersen S, Rossing P et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939